放射性栓塞治疗葡萄膜黑色素瘤肝转移的前瞻性II期试验
这项前瞻性II期试验评估了放射性栓塞治疗葡萄膜黑色素瘤肝转移的安全性和有效性。初治组(A组)23例可评估者中20例(87.0%)达到疾病控制(部分缓解9例、稳定11例),中位总生存18.5个月;免疫栓塞进展后组(B组)24例中14例(58.3%)达到疾病控制,中位总生存19.2个月。结论认为放射性栓塞是有前景的治疗方法。
要点
- A组疾病控制率87.0%(20/23),B组58.3%(14/24)。
- A组中位总生存18.5个月,B组19.2个月。
- 3级毒性包括一过性淋巴细胞减少、疼痛和恶心呕吐。
核心结论
- 放射性栓塞是治疗葡萄膜黑色素瘤肝转移有前景的方法。
研究设计与样本
- 前瞻性II期试验,2011年11月至2017年1月入组,肝肿瘤负荷小于50%的初治患者(A组)和免疫栓塞后进展患者(B组)接受放射性栓塞,每3个月行MRI、CT和PET评估肿瘤反应和肝外疾病。
关键影像表现/征象
- A组24例接受单叶(7例)、分次全肝(1例)或序贯双叶(16例)放射性栓塞,1例被排除。
- B组24例接受单叶(5例)或序贯双叶(19例)放射性栓塞。
- A组完全缓解0例、部分缓解9例、稳定11例;B组完全缓解0例、部分缓解8例、稳定6例。
诊断标准与关键数值
- A组疾病控制率87.0%(20/23,95%CI 66.4%-97.2%)。
- B组疾病控制率58.3%(14/24,95%CI 36.3%-77.9%)。
- A组肝转移中位无进展生存8.1个月(95%CI 6.4-11.8,范围3.3-33.7个月),中位总生存18.5个月(95%CI 11.3-23.5,范围6.5-73.7个月)。
- B组肝转移中位无进展生存5.2个月(95%CI 3.7-9.8,范围2.9-22.0个月),中位总生存19.2个月(95%CI 11.5-24.0,范围4.8-76.6个月)。
临床应用与阅片要点
- 治疗后每3个月行MRI、CT和PET评估肿瘤反应和肝外疾病。
- 3级治疗相关毒性包括一过性淋巴细胞减少(A组1例、B组1例)、疼痛(A组2例)和恶心或呕吐(A组1例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor. Therefore, stabilization of hepatic metastases is essential to prolonging OS. Purpose To assess the safety and effectiveness of radioembolization (RE) for treatment of UM hepatic metastases. Materials and Methods Enrollment for this prospective phase II trial began November 2011 and concluded January 2017. Treatment-naïve participants (group A) and participants who progressed after immunoembolization (group B) with hepatic tumor burden less than 50% underwent RE. Participants were followed for 1 month and every 3 months for acute and delayed toxicities, respectively. MRI, CT, and PET were performed every 3 months to evaluate for tumor response and extrahepatic disease. Participants were followed for at least 2 years or until death. Kaplan-Meier method and multivariable Cox proportional hazard models were used for data analysis. Results In group A, 24 participants (mean age ± standard deviation, 59 years ± 13; 13 men and 11 women) underwent unilobar (n = 7), fractionated whole-liver (n = 1), or sequential lobar (n = 16) RE. One participant was excluded from the trial. Complete response (n = 0), partial response (n = 9), or stable disease (n = 11) was achieved in 20 of 23 (87.0%; 95% confidence interval [CI]: 66.4%, 97.2%) participants. Median progression-free survival from liver metastasis was 8.1 months (95% CI: 6.4, 11.8; range, 3.3-33.7 months). Median OS was 18.5 months (95% CI: 11.3, 23.5; range, 6.5-73.7 months). In group B, 24 participants (mean age, 58 years ± 10; nine men and 15 women) underwent unilobar (n = 5) or sequential lobar (n = 19) RE. Complete response (n = 0), partial response (n = 8), or stable disease (n = 6) was achieved in 14 of 24 (58.3%; 95% CI: 36.3%, 77.9%) participants. Median progression-free survival from liver metastasis was 5.2 months (95% CI: 3.7, 9.8; range, 2.9-22.0 months). Median OS was 19.2 months (95% CI: 11.5, 24.0; range, 4.8-76.6 months). Grade 3 treatment-related toxicities included transient lymphopenia (group A, n = 1; group B, n = 1), pain (group A, n = 2) and nausea or vomiting (group A, n = 1). Conclusion Radioembolization is a promising treatment for patients with uveal melanoma hepatic metastases. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019. PMID: 31453767. doi:10.1148/radiol.2019190199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。